Understanding the pharmacokinetics of compounds x, y and z in Atlantic salmon

Godkjenningsdato
Godkjent fra
Godkjent til
FORSØKETS FORMÅL: The objective of the trial is to document the pharmacokinetic (PK) parameters of selected compounds in Atlantic salmon. This is a trial planned at the preliminary phase of the project and therefore the scope of the trial is limited.


FORVENTEDE SKADEVIRKNINGER PÅ DYRENE.

The experiment will be classified as mild overall as the study involves single administration of a dose that based on previous similar experiment can be considered safe. The compounds x, y and z are already tested for safety in Atlantic salmon . Therefore this study should be considered as coming within the definition of *forsøksdyrforskriften Vedlegg B Del III punkt 1b*.

FORVENTET VITENSKAPELIG ELLER SAMFUNNSMESSIG NYTTEVERDI:
Pathogen L is a persistent threat to the salmon farming sector and results in large scale economic losses. It is expected that if found promising in this study, these test compounds could be further developed as potential therapeutic agents against pathogen L.

HVOR MANGE OG HVA SLAGS DYR SOM SKAL BRUKES: 250 Atlantic salmon post smolts will be used in this study


HVORDAN KRAVENE OM ERSTATNING, REDUKSJON OG FORBEDRING SKAL ETTERLEVES

ERSTATNING: A study on live fish needs to be done because suitable invitro models to determine the pharmacokinetics (PK) of chemicals in fish are not available yet .

REDUKSJON: The number of fish used in this study is the minimum recommended fish number for analysis based on experience with analysis of similar compounds.

FORBEDRING: Fish will be euthanized by anesthetic overdose/ blow to the head for sampling. Fish will be handled gently according to internal SOPs. Use of humane endpoint (euthanizing of moribund fish) will reduce the suffering for individual fish if some adverse effect surfaces.